Bristol-Myers Squibb Co
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
U.S. President Joe Biden speaks about prescription drug costs during an event at NHTI Concord Community College in Concord, New Hampshire, U.S., October 22, 2024. REUTERS/Elizabeth Frantz Elizabeth Frantz | Reuters The Biden administration on Friday unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off […]
Read More
Stocks pop on cool inflation, hot bank earnings — plus, new rules on biotech exports to China
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Wall Street surged Wednesday thanks to the second encouraging inflation report this week and a batch of strong bank earnings. The consumer price index, excluding […]
Read More
Bristol Myers Squibb says Alzheimer’s is the biggest market for new schizophrenia drug
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In […]
Read More
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon from San Francisco! This week, Ashley and I are attending the annual JPMorgan Health Care Conference – the largest gathering of biotech and pharma execs, […]
Read More
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The U.S. Food and […]
Read More
Bargain hunting: These 8 portfolio stocks look quite cheap, but only some are worth buying
The holiday shopping season has come and gone. When it comes to stock picking, at least, the desire to find a bargain is as strong as ever. A recent analysis of our portfolio revealed we own more than a couple cheap stocks, including one of our newer additions in Bristol Myers Squibb . Still, we’re […]
Read More
We’re adding to our position in a stock that just landed a big Wall Street endorsement
Shortly after the opening the bell, we will be buying 300 shares of Bristol Myers Squibb at roughly $56.50. Following the trade, Jim Cramer’s Charitable Trust will own 1,200 shares of BMY, increasing its weighting in the portfolio to roughly 1.9% from about 1.4%. Wall Street’s stretch of bad breadth may have finally caught up […]
Read More
We want to boost our ownership of a portfolio stock that just boosted its dividend
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Thursday markets: Stocks are taking a breather after Wednesday’s big surge, especially in the Nasdaq Composite and the more narrow “Magnificent Seven” cohort. The yield on […]
Read More
Healthy Returns: Wall Street mulls over Amgen’s weight loss drug data
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Wall Street is chewing over critical […]
Read More
Our newest portfolio stock backed off its recent 52-week high — so we’re buying more
We’re buying 300 shares of Bristol-Myers Squibb at roughly $58 each. Following Wednesday’s trade, Jim Cramer’s Charitable Trust will own 900 shares of BMY, increasing its weighting to about 1.5% from 1%. Shares of pharmaceutical maker Bristol-Myers have dropped about 3% in the past two days in the absence of any real news. The stock […]
Read More